Kiora Pharmaceuticals, Inc. (KPRX)

Kiora Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	16	0	0	0	0.01	2.69
Revenue Growth (YoY)	-	-	-	-	-99.55%	62.54%
Gross Profit	16	0	0	0	0.01	2.69
Selling, General & Admin	4.69	4.66	8.28	5.32	4.66	4.41
Research & Development	5.08	4.03	3.45	5.35	3.57	5.39
Other Operating Expenses	1.9	1.9	0	4.04	0	0
Operating Expenses	11.68	10.59	11.73	14.71	8.22	9.8
Operating Income	4.32	-10.59	-11.73	-14.71	-8.21	-7.11
Interest Expense / Income	0.01	0.01	0.01	0.01	0	0
Other Expense / Income	1.41	1.82	1.96	-0.76	-1.37	-0.11
Pretax Income	2.9	-12.42	-13.7	-13.96	-6.85	-7
Income Tax	0.09	0.09	-0.11	-0.19	0.01	0.1
Net Income	2.81	-12.51	-13.58	-13.77	-6.86	-7.1
Preferred Dividends	0.53	0.53	0	0	0	0
Net Income Common	2.28	-13.04	-13.58	-13.77	-6.86	-7.1
Shares Outstanding (Basic)	3	1	0	0	0	0
Shares Outstanding (Diluted)	4	1	0	0	0	0
Shares Change	1779.59%	561.21%	203.73%	110.04%	44.34%	34.47%
EPS (Basic)	-10.08	-24.21	-166.95	-514.08	-536.40	-802.80
EPS (Diluted)	-11.34	-24.21	-166.95	-514.08	-536.40	-802.80
Free Cash Flow	7.14	-9.56	-10.42	-10.74	-7.34	-8.15
Free Cash Flow Per Share	2.48	-17.76	-128.08	-400.89	-575.28	-922.78
Gross Margin	100.00%	-	-	-	100.00%	100.00%
Operating Margin	27.02%	-	-	-	-68104.78%	-264.67%
Profit Margin	14.23%	-	-	-	-56901.65%	-264.21%
Free Cash Flow Margin	44.61%	-	-	-	-60844.56%	-303.57%
Effective Tax Rate	3.12%	-	-	-	-	-
EBITDA	2.95	-12.35	-13.55	-13.73	-6.65	-6.79
EBITDA Margin	18.41%	-	-	-	-55106.63%	-252.68%
Depreciation & Amortization	0.04	0.06	0.13	0.23	0.2	0.21
EBIT	2.91	-12.41	-13.69	-13.96	-6.85	-7
EBIT Margin	18.18%	-	-	-	-56766.97%	-260.65%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).